Immutep to Participate at the Jefferies Healthcare Conference
06/07/2023 - 08:00 AM
SYDNEY, AUSTRALIA, June 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will be presenting at the Jefferies Healthcare Conference being held on June 7-9, 2023 in New York City, NY.
Event: Jefferies Healthcare Conference Date: Thursday, 8 June 2023 Time: 10:00am – 10:25am (ET)
A live webcast of Mr. Voigt’s presentation will be available here and after the conference under the Events page within the Investors & Media section of Immutep’s website.
About Immutep www.immutep.com .
Australian Investors/Media: cstrong@citadelmagnus.com
U.S. Media: chris.basta@immutep.com
IMMP Rankings
#1726 Ranked by Stock Gains
IMMP Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
Australia
City
Sydney
About IMMP
immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
